The authors have no conflicts of interest to declare.

Prevalence of asymptomatic *Leishmania* infection in people living with HIV (PLHIV) and progression to symptomatic visceral leishmaniasis in Bihar, India

Raman Mahajan, Sophie Owen, Shiril Kumar, Shahwar Kazmi, Pradeep Das, Krishna Pandey, Neena Verma, Vikash Kumar, Amit Harshana, Estrella Lasry, Laura Moretó Planas, Emily Adams, **Sakib Burza**










Visceral leishmaniasis (VL) in India - background




MEDECINS SANS FRONTIERES DOCTORS WITHOUT BORDERS Image credit: Maps of India

- o Parasitic disease endemic in northern India, ultimately fatal
- o 80-90% of Indian VL cases occur in Bihar
- VL target of an elimination campaign on the Indian Subcontinent (ISC)
- Anthroponotic transmission on the ISC
- o Typical NTD, with limited treatments, diagnostics and





Typical evolution of the infection/disease process resulting in an asymptomatic condition (yellow) or clinically diagnosable disease (red)



- Asymptomatic Leishmania infection (ALI) 4-17 times more prevalent than symptomatic VL
- Risk of progression to symptomatic VL between 1.5 to 25%





Alvar, J., Alves, F., Bucheton, B. et al. Implications of asymptomatic infection for the natural history of selected parasitic tropical diseases. Semin Immunopathol 42, 231–246 (2020). https://doi.org/10.1007/s00281-020-00796-y

VL-HIV coinfection in India

- Challenges in diagnosis, double stigma
- Higher rates of treatment failure, relapse & mortality
- VL-HIV co-infection shown to be strongly associated with transmission at the village level
- No evidence exists in the ISC on asymptomatic leishmania infection (ALI) in PLHIV



o Evolving issue in the Indian setting: up to 20% of newly reported adult VL cases in highly endemic districts

• Most VL-HIV cases present in late stages of illness, all with advanced HIV: mutually reinforcing diseases





Study aims



This study was approved by the ethics boards of the Rajendra Memorial Research Institute of Medical Sciences, Patna, India, and Liverpool School of Tropical Medicine, UK, and the MSF Ethics Review Board. Clinical Trial Registry-India number, CTRI/2017/03/008120

To determine the prevalence of asymptomatic *Leishmania* infection in HIV cases registered at ART centres from highly VL endemic areas of Bihar and to determine the rate of progression of asymptomatic *Leishmania* cases into symptomatic VL over a period of 18 months.





Study design

Cross sectional cohort: what is the prevalence of ALI in PLHIV?

- o 1,296 consecutive consenting adult PLHIV from 4 highly endemic VL district ART centres in Bihar
- Living in a village that had reported a case of VL in the previous 24 months
- No current or previous diagnosis of VL
- Screened for ALI by serological (rK39 ELISA & rK39 RDT), and/or molecular methods (qPCR)

Prospective cohort: What happens to ALI in PLHIV over 18 months?


- Those with ALI to be followed up every 3 months for 18 months in person
- Primary endpoint: Diagnosis as symptomatic VL upto 18 months



• Those without ALI followed up by telephone every 3 months for 18 months to check health status



Flow Diagram – Cross sectional survey



Total Non asymptomatic = n=1200





Diagnostics basket of choice

o rK39 RDT and ELISA detect anti-*Leishmania* antibodies present in the blood of patients with but currently used only in research as no standardization in VL



- *Leishmania* infection. RDT may fail to detect low antibody titres and cannot be used in relapses
- o Quantitative polymerase chain reaction (qPCR) considered a proxy for parasite load. Highly sensitive,
- Leishmania antigen ELISA Urine novel non-invasive test to detect *leishmania* antigens in the urine




Prevalence of asymptomatic *Leishmania* infection in PLHIV living in highly endemic VL areas

Number of HIV patients testing positive for asymptomatic *Leishmania* infection

	Ν
Total recruited	1296
Total asymptomatic <i>Leishmania</i> infection	96
Total positive with rK39 RDT	5
Total positive by rk39 ELISA	96
Total positive by qPCR	6
(Total positive by Leishmania antigen ELISA in urine	28







Predictors of asymptomatic Leishmania infection

	All participants N (%)	Non- <i>Leishmania</i>	Asymptomatic infection (ALI)	Odds Ratio (95%CI)	P value
		infected			
		N (%)	N (%)		
CD4 (cells / μL)					
< 100	35 (12.7)	29 (2.4)	6 (6.3)	3.1 (1.2, 7.6)	0.012
100 - 199	104 (8.0)	91 (7.6)	13 (13.5)	2.1 (1.1, 4.0)	0.019
200 - 299	179 (13.8)	164 (13.7)	15 (15.6)	1.4 (0.8, 2.4)	0.316
≥ 300	978 (75.5)	916 (76.3)	62 (64.6)		
Household size					
< 5	395 (30.5)	376 (31.3)	19 (19.8)		
≥ 5	901 (69.5)	824 (68.7)	77 (80.2)	1.8 (1.1, 3.2)	0.016
Number of IRS in last 18 months					
0	140 (10.8)	133 (11.1)	7 (7.3)	0.5 (0.2, 1.2)	0.103
1	132 (10.2)	128 (10.7)	4 (4.2)	0.3 (0.1, 0.9)	0.020
2	642 (49.5)	593 (49.4)	49 (51.0)	0.8 (0.5, 1.3)	0.317
> 2	382 (29.5)	346 (28.8)	36 (37.5)		

Factors <u>not</u> associated with ALI: Age, sex, Socioeconomic status, type of house, proximity to pond/livestock, month of IRS spray, use of bed nets, ART usage status, TB infection, BMI





Prospective cohort: Progression to symptomatic infection

- 3 out of 4 progressed within 3 months; 1 at month 12
- Conversion rates of participants identified as positive:

o rK39 ELISA - 3.7% (4/109)

o rK39 RDT - 40% (2/5)

o qPCR - 57% (4/7)

o Leishmania antigen ELISA - 14% (4/29)

o Risk of all-cause mortality in ALI 6.4% (n=7) compared with 2.5% (n=30) in those without (risk ratio, RR, 2.6, 95% CI 1.2-5.7, p=0.018)



o 3.7% (4/109) participants progressed from asymptomatic to symptomatic infection over 18 months



Conclusions and recommendations

- PLHIV living in highly VL-endemic areas have a relatively high prevalence of asymptomatic *leishmania* infection in India
- Progression rates to symptomatic infection appear relatively low
- None of currently available diagnostic tools useful in predicting progression
- However, all cause mortality rates higher compared to non-Leishmania infected
- More studies needed to investigate impact early 'prophylactic' treatment of ALI in PLHIV considering poor outcomes in VL-HIV patients
- Role of screening within advanced HIV diagnostic packages in endemic areas?



